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Natural killer T (NKT) cells are a subset of CD1d-restricted T  cells at the interface 
between the innate and adaptive immune system. NKT cells can be subdivided into 
functional subsets that respond rapidly to a wide variety of glycolipids and stress-related 
proteins using T- or natural killer (NK) cell-like effector mechanisms. Because of their 
major modulating effects on immune responses via secretion of cytokines, NKT cells 
are also considered important players in tumor immunosurveillance. During early tumor 
development, T helper (TH)1-like NKT cell subsets have the potential to rapidly stimu-
late tumor-specific T cells and effector NK cells that can eliminate tumor cells. In case 
of tumor progression, NKT  cells may become overstimulated and anergic leading to 
deletion of a part of the NKT cell population in patients via activation-induced cell death. 
In addition, the remaining NKT cells become hyporesponsive, or switch to immunosup-
pressive TH2-/T regulatory-like NKT cell subsets, thereby facilitating tumor progression 
and immune escape. In this review, we discuss this important role of NKT cells in tumor 
development and we conclude that there should be three important focuses of future 
research in cancer patients in relation with NKT  cells: (1) expansion of the NKT  cell 
population, (2) prevention and breaking of NKT cell anergy, and (3) skewing of NKT cells 
toward TH1-like subsets with antitumor activity.
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iNTRODUCTiON




cell	 (2).	These	subsets	 include	natural	killer	T	(NKT)	cells	 that	
feature	characteristics	of	both	conventional	T cells	 and	natural	
killer	 (NK)	 cells.	 Upon	 activation,	 NKT  cells	 are	 able	 to	 kill	
target	cells	either	directly	(3–5)	or	indirectly	by	influencing	both	
myeloid-	 and	 lymphoid-derived	 immune	 cells	 (6).	 Moreover,	












are	 addressed	 in	 healthy	 individuals.	 Thereafter,	 the	 role	 of	
NKT  cells	 is	 discussed	 in	 the	 development	 and	progression	 of	
cancer.	 Finally,	 available	NKT  cell-based	 immunotherapies	 are	
presented	and	possibilities	for	future	research	are	discussed.













invariant	 TCR	α-chain.	The	 type	 I	NKT  cell	 subset	 recognizes	
the	 glycosphingolipid	 α-galactosylceramide	 (α-GalCer)	 or	 its	
synthetic	 analogs	 when	 presented	 by	 major	 histocompatibility	
complex	(MHC)	class	I-like	CD1d	molecules	(10–12).	Four	years	
after	 the	 identification	of	 the	 invariant	Vα14Jα18	TCR	α-chain	
in	mice,	the	human	counterpart	Vα24Jα18	was	discovered	which	









II	molecules	 on	 cortical	 thymic	 epithelial	 cells	 are	 selected	 to	
undergo	lineage	commitment	(9).	This	process	leads	to	matura-
tion	 of	CD4+	 or	CD8+	 T  cells	 that	 recognize	MHC-presented	
peptides.	 Alternatively,	 type	 I	 NKT  cells	 that	 express	 the	
randomly	 rearranged	 invariant	 Vα14Jα18	 chain	 are	 positively	
selected	upon	binding	to	CD1d	molecules	expressed	by	cortical	
thymocytes	 (9,	 20–22).	 As	 a	 result	 of	 this	 alternative	 positive	
selection,	 they	 recognize	 lipid-derived	 antigens	 presented	 by	
CD1d	molecules	(10).	During	the	maturation	process,	a	part	of	
the	type	I	NKT cell	population	retains	expression	of	the	T cell-
associated	marker	CD4,	resulting	 in	 two	major	populations	 in	
mice:	CD4+CD8−	 and	CD4−CD8−	 (double	 negative,	DN)	 type	
I	 NKT  cells	 (23,	 24).	 In	 addition,	 Type	 I	 NKT  cells	 acquire	
expression	of	 the	natural	 killer	 receptor	 (NKR)	NK1.1	during	
maturation	(9).
Development of Type i NKT Cells  
in Humans
Although	 the	 thymic	development	of	 type	 I	NKT cells	 is	well	
defined	 in	 mice,	 it	 has	 not	 as	 yet	 been	 studied	 in	 details	 in	
humans.	It	has	been	reported	that	NKT	precursor	cells	can	be	
identified	 in	 thymic	 tissue	derived	 from	human	embryos	 and	
young	 children	 (25,	26).	 Similar	 to	 type	 I	NKT  cell	 develop-
ment	 in	 mice,	 human	 type	 I	 NKT  cells	 express	 cell	 surface	
markers	that	are	usually	associated	with	both	T-	and	NK cells.	
For	 instance,	a	part	of	 the	human	type	I	NKT cell	population	
retains	 expression	 of	 the	 T  cell-associated	 markers	 CD4	 or	
CD8	during	maturation,	 resulting	 in	 three	major	populations	
in	humans:	CD4+CD8−,	CD4−CD8+,	and	DN	type	I	NKT cells	
(27,	 28).	 In	 addition,	 a	 part	 of	 the	 human	 type	 I	 NKT  cells	




Localization of Type i NKT Cells  
in Humans
After	 development	 and	 maturation	 in	 the	 thymus,	 NKT  cells	
migrate	 to	 the	 periphery.	 In	 general,	 human	 type	 I	NKT  cells	
are	 present	 in	 small	 numbers	 (<0.1%	of	 total	 T  lymphocytes)	
in	 peripheral	 blood	 (PB),	 lymph	 nodes,	 spleen,	 thymus,	 lung,	
and	 bone	 marrow	 (32–34),	 whereas	 larger	 type	 I	 NKT  cell	
populations	 reside	 in	 the	 liver,	 colon,	 kidney	 (~1%	 of	 total	






Morphology of NKT Cells
Despite	the	fact	that	NKT cells	are	derived	from	the	T cell	line-
age,	their	morphology	resembles	NK cells	more	closely.	NK	and	
NKT  cells	 are	 both	 referred	 to	 as	 large	 granular	 lymphocytes,	
whereas	T cells	are	described	as	small	and	non-granular	(40–42).	
FigURe 1 | Overview of the different functional human NKT cell subsets. CD1d-restricted human NKT cells can be divided into subsets based on their  
TCR repertoire and cytokine profile. Type I NKT cells express the invariant Vα24Jα18 TCR α-chain and can be subdivided into five distinct functional subsets 
(indicated in green). In addition, type II NKT cells express a diverse TCR repertoire and can be subdivided into two functional subsets (indicated in blue). Upon 
activation, NKT cells secrete a unique pattern of cytokines, indicated for each subtype. Type I and type II NKT cells are able to switch between different functional 
subsets upon interactions within the TME. Abbreviations: NKT, natural killer T; TCR, T cell receptor; TH, helper T; Treg, regulatory T; TFH, follicular helper T; TME,  
tumor microenvironment.
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iDeNTiFiCATiON OF HUMAN  
NKT CeLL SUBSeTS















IL-13	 upon	 activation	 (7,	 30,	 46).	This	 type	 I	NKT  cell	 subset	
mainly	 consists	 of	CD4+CD8−	 cells	which	 are	 able	 to	 suppress	
immune	responses	in	various	disease	models	(47–49).	Recently,	
three	additional	minor	type	I	NKT cell	subsets	were	identified.	
TH17-like	 type	 I	NKT  cells	 have	 been	 described,	 secreting	 the	









nently	determined	at	 this	 time	since	 their	cytokine	production	





via	 CD28	 (58),	 thereby	 implying	 plasticity	 of	 type	 I	NKT  cell	
subsets.
identification of Type i NKT Cell Subsets
NKT  cells	 can	 be	 identified	 from	 human	 peripheral	 blood	
mononuclear	cells	(PBMCs)	with	flow	cytometry	using	mono-
clonal	antibodies	(mAb)	and	multimers	as	thoroughly	described	
by	 Metelitsa	 (59).	 For	 instance,	 type	 I	 NKT  cells	 have	 often	
been	 identified	by	 costaining	with	 anti-Vα24	 (clone	C15)	 and	
anti-Vβ11	 (clone	 C21)	 mAb	 (27,	 29,	 60,	 61).	 However,	 this	
mAb	 combination	 leads	 to	 overestimation	 of	 type	 I	NKT  cell	
numbers	since	conventional	T cells	can	also	express	Vα24	and	
Vβ11	TCR	subunits	(62,	63).	Alternatively,	type	I	NKT cells	can	
be	 detected	 with	 anti-Vα24Jα18	 (Clone	 6B11)	 mAb	 (28,	 31).	
Furthermore,	α-GalCer-loaded	CD1d	dimers	(64)	and	tetramers	
(30,	65–67)	 can	be	used	 to	 specifically	detect	CD1d-restricted	








Phenotype of Type i NKT Cell Subsets
Type	 I	NKT cells	 constitutively	 express	 various	T  cell	markers	
such	 as	 the	 TCR	 signaling	 complex	 CD3,	 and	 costimulatory	
receptors	such	as	CD4,	CD8,	and	CD28	(27–31).	CD4	is	expressed	
4
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by	15–80%	of	the	type	I	NKT cell	population	(27–29,	31)	and	is	
sometimes	 used	 to	 subdivide	 type	 I	NKT  cells	 into	CD4−	 and	
CD4+	 populations.	 Besides,	 type	 I	 NKT  cells	 constitutively	
express	various	receptors	that	are	usually	observed	on	NK cells,	
such	 as	 the	 adhesion	molecule	 CD56	 and	 the	 activating	NKR	
CD161	(27–30).	17–70%	of	 the	CD4−	 type	I	NKT cells	express	
CD56,	 in	 contrast	 to	 only	 a	 small	 fraction	 of	 the	CD4+	 type	 I	
NKT cell	population	(3–11%)	(29).	Interestingly,	type	I	NKT cells	







In	 addition,	 type	 I	 NKT  cells	 have	 the	 ability	 to	 induce	
expression	 of	 a	 number	 of	 phenotypic	markers	 upon	 activa-
tion	 and/or	 interactions	 within	 the	 microenvironment.	 For	
instance,	 type	 I	NKT  cells	 can	 upregulate	CD62L	 expression	
upon	α-GalCer-mediated	activation	and	expansion	which	can	
serve	 as	 a	 marker	 for	 NKT  cells	 with	 superior	 survival	 and	
proliferative	 capacity	 (70).	 In	 addition,	 CD4+	 and	 DN	 type	







α-GalCer,	 whereas	 its	 expression	 is	 upregulated	 in	 activated	
T  cells	 (72,	 73).	This	 downregulation	 could	 be	 related	 to	 the	
fact	 that	 NKT  cells	 already	 constitute	 a	 memory	 phenotype	
and,	 therefore,	 do	 not	 require	 CD27	 to	 generate	 NKT  cell	








among	healthy	 individuals	 (1–85%)	 and	 can	be	 altered	upon	
interactions	within	the	TME	(31,	56,	74–78).	In	addition	to	the	
expression	of	NK-	and	T cell-associated	cell	surface	markers,	
type	 I	NKT cells	 express	a	wide	 range	of	 inducible	cytokine-	
and	chemokine	receptors	enabling	them	to	respond	to	various	
signals	(28–31,	79–81).	For	instance,	type	I	NKT cells	 induce	
expression	 of	 the	 IL-2	 receptor	 chain	 CD25	 (IL-2RA)	 upon	
α-GalCer-mediated	 activation	 (28,	 29,	 31),	 primarily	 in	
the	 CD4+	 type	 I	 NKT  cell	 population	 (30).	 A	 different	 pat-
tern	 is	 observed	 regarding	 the	 chemokine	 receptors	 CCR5,	
CCR6,	CCR7,	and	CXCR6,	which	are	all	higher	expressed	on	
CD4−	type	I	NKT cells	compared	with	CD4+	type	I	NKT cells	




Functional Type ii NKT Cell Subsets
So	 far,	 two	 distinct	 functional	 type	 II	 NKT  cell	 subsets	 have	
been	identified	(Figure 1).	TH1-like	type	II	NKT cells	secrete	the	
pro-inflammatory	 cytokines	 IFN-γ	 and	 TNF-α	 upon	 stimula-
tion,	whereas	TH2-like	 type	II	NKT cells	 secrete	 the	regulatory	




identification of Type ii NKT Cell Subsets









used	 due	 to	 the	 unstable	 nature	 of	 sulfatide-loaded	 CD1d	
complexes.	 Furthermore,	 since	 not	 all	 type	 II	NKT  cells	 are	






In	many	 studies,	NKT cells	 are	 identified	with	flow	 cytometry	
using	a	combination	of	anti-CD3	and	anti-CD56	mAb	(31,	81,	
91–94).	Although	 it	 is	 likely	 that	 the	CD3+CD56+	 cell	 popula-
tion	includes	CD1d-restricted	NKT cells,	it	has	to	be	taken	into	







a	 significant	 proportion	 of	 type	 I	 NKT  cells	 is	 excluded	 from	
analyses	when	using	the	combination	of	anti-CD3	and	anti-CD56	




interaction	 with	 human	 leukocyte	 antigen	 (HLA)	molecules	
(31,	95,	96).	KIRs	are	primarily	expressed	by	NKT-like	cells,	and	
not	by	type	I	NKT cells.
In	 conclusion,	 different	 functional	NKT  cell	 subsets	 can	 be	
identified	within	 the	 type	 I	 and	 type	 II	NKT  cell	 populations.	
Although	 type	 I	NKT  cells	 are	 characterized	 in	 detail,	 type	 II	




FigURe 2 | CD1d-presented glycolipids in APC. APC present exogenous and endogenous glycolipids in the context of CD1d. During endosomal trafficking, CD1d 
molecules relocate from the cell membrane toward a late endosome where the bound glycolipid antigens are removed from CD1d and replaced by new glycolipid 
antigens. Exogenous glycolipids (indicated in blue) enter the APC late endosome via endocytosis or phagocytosis (1). Endogenous glycolipids (indicated in purple) 
enter the late endosome as a result of NOD, FPR2, or TLR signaling (2), but the exact mechanism is unknown. The exogenous and endogenous glycolipids are 
loaded into CD1d molecules upon which they relocate back to the cell membrane. Abbreviations: APC, antigen-presenting cells; NOD, nucleotide-binding 
oligomerization domain; FPR2, formyl peptide receptor 2; TLR, toll-like receptor.
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Activation via T Cell-Like Mechanisms
First,	 NKT  cells	 can	 be	 activated	 via	 their	 TCR	 in	 a	 T  cell-
like	 manner	 via	 recognition	 of	 glycolipids	 in	 the	 context	 of	





(Figure  2).	 Exogenous	 microbial-	 and	 non-microbial-derived	





Furthermore,	 exogenous	 glycolipids	may	 enter	APC	with	 very	
FigURe 3 | Activation of NKT cells. Activation of NKT cells is dependent on 
a balance between activating and inhibitory signals. First of all, NKT cells 
receive activating signals via their TCR that recognize glycolipids in context of 
CD1d. Second, NKT cells receive activating signals in a CD1d-independent 
manner via NKRs upon interaction with stress proteins such as MIC-A and 
MIC-B, ULBPs, Nectin-2, or MLL5 proteins. In addition, NKT cells receive 
activating signals in a CD1d-independent manner via KIRs with merely 
unknown ligands. Inhibitory NKRs and KIRs that recognize HLA molecules 
provide inhibitory signals that are able to disrupt both TCR and NKR 
signaling. When the balance is skewed toward activation, NKT cells produce 
and secrete high amounts of cytokines. In addition, NKT cells that are 
activated via this mechanism are able to kill target cells directly via activation 
of their TCRs and NKRs. Finally, NKT cells—like NK cells—can be activated 
by a combination of IL-12 and IL-18 which leads to production of cytokines. 
Abbreviations: NKT, natural killer T; TCR, T cell receptor; NKR, natural killer 
receptor; MIC, major histocompatibility complex I-like molecules; ULBP, 
unique long-binding protein; MLL5, mixed-lineage leukemia-5; KIR,  
killer-cell Ig-like receptor; HLA, human leukocyte antigen; NK, natural killer.
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During	 endosomal	 trafficking,	 CD1d	 molecules	 relocate	 from	
the	 cell	 membrane	 toward	 a	 late	 endosome	 where	 the	 bound	
glycolipids	 are	 removed	 from	CD1d	 and	 replaced	 by	 new	 gly-
colipids	 (Figure 2)	 (102,	103).	Thereafter,	 the	CD1d	molecules	
relocate	back	to	the	cell	membrane.	In	addition,	APC	also	present	
endogenous	glycolipids	in	the	context	of	CD1d	(Figure 2).	For	
instance,	 activation	 of	 nucleotide-binding	 oligomerization	
domain-1	 and	 -2	 intracellular	pattern	 recognition	 receptors	by	
bacteria,	 or	 activation	 of	 formyl	 peptide	 receptor	 2	 by	 serum	
amyloid	A-1,	 results	 in	 loading	of	 endogenous	 glycolipids	 into	
CD1d	molecules	during	endosomal	CD1d	trafficking	(Figure 2)	
(104,	 105).	 Furthermore,	 toll-like	 receptor	 signaling	 upon	 sti-
mu	lation	 with	 lipopolysaccharide	 was	 suggested	 to	 result	 in	
the	 loading	 of	 endogenous	 glycolipids	 into	 CD1d	 molecules	
(100,	 106).	The	exact	mechanism	of	how	 these	 signaling	path-
ways	lead	to	the	loading	of	endogenous	glycolipids	into	CD1d	is,	
however,	unknown.
In	 contrast	 to	 TCRs	 on	 conventional	 T  cells	 that	 recog-
nize	 specific	 peptides	 presented	 by	 MHC	 class	 I	 or	 II,	 the	
Vα24Jα18	 TCR	 present	 on	 type	 I	 NKT  cells	 recognizes	 a	
diversity	of	glycolipids	 that	are	presented	by	CD1d	molecules.	
For	 instance,	 type	 I	 NKT  cells	 recognize	 glycosphingolipids,	
α-galactosyldiacylglycerols,	 diacylglycerols,	 and	 phospholipids	
derived	from	mycobacteria	in	addition	to	α-GalCer	(107–111).	
Furthermore,	 type	I	NKT cells	can	be	activated	upon	encoun-
tering	 the	 self-glycolipids	 isoglobotrihexosylceramide	 and	
β-glucosylceramide	 (11,	 112).	 In	 addition,	 type	 II	 NKT  cells	






CD1d-dependent	manner	 (115).	This	 antigen-specific	 cytotox-
icity	 is	 CD95/CD95L	 dependent,	 unlike	 NK-	 and	 T  cells	 that	





















Activation via NK Cell-Like Mechanisms
NKT cells	seem	to	behave	similar	to	NK cells	when	it	comes	to	
their	activation.	Like	in	NK cells,	activation	is	dependent	on	the	





“stress	proteins.”	For	 instance,	 the	NKG2D	receptor	 recognizes	
MHC	 class	 I-like	molecules	 (MIC)	A	 and	B	 and	unique	 long-
binding	proteins	(123),	whereas	DNAM-1	recognizes	the	poliovi-
rus	receptor	and	Nectin-2	(124).	Besides,	NKT cells	express	KIRs,	
with	 less	 well-defined	 ligands,	 that	 provide	 activating	 signals	
(125–128).	Furthermore,	NKT cells	express	NKRs	and	KIRs	that	
provide	 inhibitory	 signals	 upon	 binding	 with	 HLA	molecules	
(129–134).	When	the	balance	of	signals	is	shifted	toward	activa-
tion,	an	NKT cell	 is	activated,	resulting	in	cytokine	production	
as	well	 as	direct	 killing	of	 tumor	 cells	 in	 a	CD1d-independent	
manner	(Figure 3).	Interestingly,	studies	showed	that	inhibitory	
7
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signals	 provided	 by	KIRs	 and/or	NKRs	were	 able	 to	 interrupt	
TCR	signaling	in	conventional	T cells	without	CD1d	restriction	
(31,	130,	131,	133).	 Since	NKT cells	 express	 similar	 functional	
receptors,	 it	 is	 likely	that	similar	 interruption	of	TCR	signaling	
also	occurs	 in	NKT cells	 (Figure  3).	 In	 addition,	 a	part	of	 the	
NKT cell	population	expresses	the	low	affinity	Fc	receptor	CD16	












secrete	 high	 amounts	 of	 IFN-γ,	 as	 also	 observed	 after	 CD1d-
dependent	and	NKR-mediated	activation	(127,	136,	137,	142).
NKT Cell Anergy
Importantly,	 murine	 studies	 have	 indicated	 that	 overstimula-
tion	and	chronic	activation	of	 type	 I	NKT cells	with	α-GalCer	








attenuator	 (144,	 146,	 150),	 resulting	 in	 hyporesponsiveness.	







α-GalCer	 restimulation.	 By	 contrast,	 anergic	 type	 I	 NKT  cells	
retained	 their	 capacity	 to	 produce	 TH2-associated	 cytokines	






















T  cell	 function	 and	 drive	 TH2	 differentiation,	 respectively	 (49,	
158–160).	 IL-10,	 produced	 by	Treg-like	 type	 I	NKT  cells	 drives	






In	 addition	 to	 production	 of	 large	 amounts	 of	 cytokines	 as	
discussed	earlier,	NKT cells	secrete	a	range	of	chemokines	upon	
activation,	 including	 RANTES,	 Eotaxin,	MIP-1α,	 and	MIP-1β,	
that	 lead	 to	 the	attraction	of	NK cells,	neutrophils,	and	mono-
cytes	toward	the	inflammatory	microenvironment	(166).	IFN-γ	
secreted	 by	 TH1-like	 NKT  cell	 subsets	 then	 leads	 to	 the	 local	
activation	of	NK cells,	neutrophils,	and	macrophages	(167–169).	
Furthermore,	 granulocyte	macrophage	 colony-stimulating	 fac-
tor	(GM-CSF),	IFN-γ,	and	IL-4	secreted	by	NKT cells	may	shift	
the	 functional	 capacity	 of	 monocytes	 toward	 a	 more	 DC-like	






















THe IN VITRO AND IN VIVO ANTiTUMOR 
ACTiviTY OF NKT CeLLS
Type i NKT Cells in Tumor immunity
Twenty	years	ago,	it	was	first	reported	that	the	glycolipid	α-GalCer,	
discovered	 in	 marine	 sponges,	 had	 potent	 antitumor	 activity	
in vivo	(172–174).	Mice	that	were	intravenously	inoculated	with	
FigURe 4 | The regulatory function of activated NKT cells. Upon activation, NKT cells have a major influence on other immune cells. NKT cells can induce full 
maturation of DC upon which they activate T cells and induce TH1 differentiation. Activated T cells interact with B cells resulting in their activation, as well as 
production of immunoglobulins and affinity maturation. The TFH type I NKT cell subset provides cognate help for B cells which promotes the production of 
immunoglobulins and affinity maturation. In addition, NKT cells can reverse the phenotype of immune suppressive neutrophils. Upon activation, NKT cells are also 
able to activate NK cells and macrophages and induce a functional shift of monocytes toward a DC-like phenotype. Finally, NKT cells can drive T cell differentiation 
to either a TH1-, TH2-, or Treg-profile, dependent on the NKT subsets involved. Abbreviations: NKT, natural killer T; DCs, dendritic cells; TH, helper T; TFH, follicular 
helper T; NK, natural killer; Treg, regulatory T; N, neutrophil; MΦ, macrophage.
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provided	curative	outcomes	 in	~45%	of	 the	mice.	Thereafter,	 it	
was	 shown	 that	 α-GalCer-pulsed-DC	 could	 also	 be	 combined	
with	 the	 chemotherapeutics	 cyclophosphamide	 or	 gemcitabine	
to	 enhance	 survival	 of	 mice	 with	 metastatic	 disease	 (184).	
Importantly,	 studies	 showed	 that	 the	 anti-metastatic	 effect	 of	
α-GalCer	was	 impaired	 in	NK cell-depleted	or	 IFN-γ-deficient	
mice	(185,	186).	Smyth	et al.	showed	that	IFN-γ	production	by	
type	I	NKT cells	and	subsequent	IFN-γ	production	by	NK cells	
was	 crucial	 for	α-GalCer-mediated	 tumor	 protection	 (177).	 In	
line	 with	 these	 results,	 it	 was	 observed	 that	 the	 TH2-skewing	
synthetic	α-GalCer-analog	OCH	provided	less	tumor	protection	
in	 the	CT26	mouse	model	 compared	with	α-GalCer	 (187).	By	
contrast,	studies	reported	that	analogs	of	α-GalCer,	which	skewed	
the	 cytokine	 profile	 of	 type	 I	NKT  cells	 toward	TH1,	 provided	
superior	protection	against	metastases	formation	compared	with	












directly	via	CD1d	 interaction,	 they	need	 to	present	glycolipids	
that	 can	 be	 recognized	 by	 NKT  cells.	There	 is	 evidence	 from	
murine	studies	that	type	I	NKT cells	can	be	activated	by	tumor-
derived	glycolipids	that	are	cross-presented	by	APC	in	the	context	
of	 CD1d	 (196–199).	 However,	 until	 now,	 the	 nature	 of	 tumor	










of	 CD1d.	Moreover,	 although	 type	 I	NKT  cells	 are	 capable	 of	











type	 II	NKT cells	 are	 associated	with	 immunosuppression	and	









produce	 IL-13	 through	 the	 IL-4R–STAT6	 pathway,	 which	 was	
necessary	 for	downregulation	of	 tumor	 immunosurveillance	 in	
a	 15-12RM	fibrosarcoma	mouse	model	 (49).	Thereafter,	 it	was	
shown	 that	 IL-13	 induced	 TGF-β-secreting	 myeloid-derived	




















THe FUNCTiON AND PHeNOTYPe OF 
NKT CeLLS iN PATieNTS DiAgNOSeD 
wiTH CANCeR





tumor	 tissue	 and	 non-tumor	 tissue.	 The	 frequency	 of	 type	 I	
NKT cells	was	reported	to	be	higher	 in	 intrahepatic	malignant	
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liver	 metastases	 compared	 with	 healthy	 liver	 tissue	 (35).	 In	
addition,	several	studies	showed	a	correlation	between	infiltrat-
ing	NKT cell	numbers	and	clinical	outcome.	High	numbers	of	
tumor-infiltrating	 type	 I	NKT  cells	 correlated	with	 a	 relatively	
good	clinical	outcome	in	patients	diagnosed	with	colorectal	can-
cer	and	neuroblastoma	(209,	210).	High	density	of	NK/NKT cells	
was	 also	 associated	with	prolonged	overall	 survival	 in	periam-
pullary	 adenocarcinoma	 (including	pancreatic	 cancer)	 patients	
(211).	Accordingly,	absence	of	infiltrating	type	I	NKT cells	and	
low	numbers	of	infiltrating	NKT-like	cells	correlated	with	poor	






in	 tumor-bearing	 livers	 compared	 with	 normal	 livers	 (35).	
In	 addition,	 in	 a	 study	 on	 colorectal	 cancer,	 expression	 of	 the	






I	 NKT  cell	 infiltration	 in	 neuroblastomas	 was	 associated	 with	
























type	 I	NKT  cells	 in	 cancer	 patients.	 For	 instance,	 the	 number	
of	 circulating	 type	 I	 NKT  cells	 was	 significantly	 decreased	 in	
patients	with	different	 cancers	 compared	with	healthy	 controls	
(213–221).	In	line	with	the	results	on	infiltrating	type	I	NKT cells,	
low	 circulating	 type	 I	NKT  cell	 numbers	 correlated	with	 poor	
clinical	outcome	in	patients	with	head	and	neck	squamous	cell	
carcinoma	 (214,	 215).	 Interestingly,	 late-stage	 cancer	 patients	
presented	with	lower	type	I	NKT cell	numbers	than	early-stage	
cancer	patients	with	oral	squamous	cell	carcinoma	or	laryngeal	







are	 often	 functionally	 impaired	 in	 patients	 (216,	 218,	 219,	
222–224).	For	instance,	circulating	type	I	NKT cells	derived	from	











In	 conclusion,	 reduced	 frequency	 of	 circulating	 NKT  cells	
and	 altered	 phenotype,	 resulting	 in	 altered	 function,	 of	 both	
infiltrating	 and	 circulating	 NKT  cells	 are	 often	 observed	 in	
cancer	 patients,	 especially	 in	 patients	 with	 late-stage	 disease.	
Since	altered	function	was	not	observed	in	infiltrating	NKT cells	
in	healthy	 tissue,	 it	 can	be	 argued	 that	 this	 altered	 function	of	
NKT  cells	 is	 cancer/TME	mediated:	 tumors	may	 suppress	 the	
immune	system,	and	skew	the	cytokine	profile	of	NKT cells	from	
TH1	 toward	 TH2	 to	 escape	 from	 recognition	 and	 elimination.	
Although	 the	 mechanisms	 behind	 the	 cancer/TME-mediated	
altered	 function	of	NKT cells	are	not	 fully	understood,	 studies	
suggested	 a	 role	 for	metabolic	 derivative	 lactic	 acid	 (225),	 the	
production	of	soluble	factors	by	tumors	such	as	sMIC	(226),	and	
the	expression	of	CD1d	by	tumors	(194,	227).
SHAPiNg THe TMe BY NKT CeLLS
Shaping the TMe by TH1-Like NKT Subsets







killing	 of	 TAM	 that	 cross-presented	 tumor-derived	 glycolipids	
in vivo	(197,	229).	Furthermore,	TH1-like	NKT cells	and	second-
ary	 activated	 NK  cells	 contributed	 to	 the	 inhibition	 of	 tumor	
angiogenesis	 by	 IFN-γ	 via	 suppression	 of	 M2-polarized	 TAM	
FigURe 5 | The dual role of NKT cells in cancer. During early tumor development, TH1-like NKT cells may induce an effective antitumor response via direct killing of 
tumor cells upon interaction with stress proteins and CD1d molecules, respectively. In addition, activated TH1-like NKT cells secrete high amounts of IFN-γ, which 
may lead to generation of tumor-specific CD8+ cytotoxic T cells and rapid activation of NK cells that kill tumor cells. Besides, activated NKT cells can induce 
maturation of DC in a CD1d-dependent manner, resulting in TH1 differentiation and activation of tumor-specific CD8+ T cells. Finally, activated TH1-like NKT cells can 
kill M2-polarized TAM in a CD1d-dependent manner, thereby preventing their tumor growth-promoting effects. During tumor progression, TH1-like NKT cells can 
become anergic and may switch to TH2-/Treg-like NKT cell subsets that facilitate tumor progression and immune escape. For instance, Treg-like NKT cells can 
promote differentiation of M2-polarized TAM and Tregs. Tregs inhibit tumor-specific T cells via cell–cell interactions, and secretion of IL-10 and TGF-β. In addition, 
TH2-like NKT cells can inhibit tumor-specific T cells via production of large amounts of IL-13. TH2- and Treg-like NKT cell subsets might be able to kill tumor cells, 
either via CD1d-dependent or CD1d-independent mechanisms. However, overstimulated NKT cells produce large amounts of immunosuppressive cytokines, 
resulting in a net effect of immunosuppression. Receptors that are known to be involved in NKT cell-mediated antitumor responses are indicated in the figure. The 
functional NKT cell subsets indicated in the figure can be both type I and type II NKT cells as illustrated in Figure 1. Abbreviations: NKT, natural killer T; TH, helper T; 
NK, natural killer; DCs, dendritic cells; TAM, tumor-associated macrophages; Treg, regulatory T; TME, tumor microenvironment; NKR, natural killer receptor; TCR, 
T cell receptor; HLA, human leukocyte antigen.
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the	presence	of	TH1-like	 type	 I	NKT cells	might	minimize	 the	
presence	of	tumor	growth-promoting	M2-polarized	TAM	in	the	
TME.	 On	 the	 other	 side,	 an	 immature	 tolerogenic	 DC	 subset	
12
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DC,	 the	presence	of	 immature	 tolerogenic	DC	might	be	mini-
mized	in	tumors	where	sufficient	numbers	of	these	NKT cells	are	
present.	 Importantly,	 TH1-like	 NKT  cells	 are	 able	 to	 stimulate	
both	tumor	antigen-restricted	T cells	that	recognize	tumor	cells	
with	HLA	expression	and	effector	NK cells	that	eliminate	tumor	









tumors	 including	 carcinomas,	 sarcomas,	 neuroblastomas,	 and	
melanomas	(239–242).	Since	inhibitory	NKRs	and	KIRs	prevent	
NKT  cell	 activation	 upon	 interaction	 with	 HLA	 molecules	
(Figure 3),	NKT cells	might	be	able	to	directly	kill	 tumor	cells	
with	 low	HLA	 expression,	 similar	 to	NK  cells.	NKT  cells	may	
have,	however,	primarily	a	 regulatory	 function,	 suggesting	 that	
the	antitumor	activity	mediated	by	direct	killing	of	tumor	cells	is	
of	lesser	importance.
Shaping the TMe by TH2-/Treg-Like  
NKT Subsets
As	discussed	 in	 the	previous	chapter,	 the	phenotype	and	 func-
tion	 of	 TH1-like	 subsets	 is	 frequently	 altered	 in	 patients.	 The	
NKT cell	population	in	patients	is	skewed	toward	a	TH2	profile,	
proliferative	 impaired	 and,	 in	 addition,	 reduced	 in	 size.	These	






on	 this	hypothesis,	we	propose	 that	TH1-like	NKT cells	 induce	
an	effective	antitumor	response	during	early	tumor	development	
and	perhaps	prevent	further	tumor	development	in	many	cases.	
However,	 in	 some	 cases,	 at	 some	point	 during	 tumor	 progres-
sion,	NKT cells	become	overstimulated.	As	a	result,	a	part	of	the	
NKT cell	population	is	deleted	in	cancer	patients	via	AICD.	In	
addition,	 the	 remaining	NKT  cells	 become	hyporesponsive,	 or	
switch	 to	 TH2-/Treg-like	 NKT  cell	 subsets,	 thereby	 facilitating	




large	 amounts	 of	 IL-13	 and	 IL-10,	 respectively,	 that	 suppress	
the	 TME	 (i.e.,	 via	 fibroblasts	 and	 MDSC),	 thereby	 indirectly	
stimulating	 tumor	progression.	 In	 addition,	Treg-like	NKT  cells	
promote	differentiation	of	M2-polarized	TAM	and	Tregs	that	are	
also	able	to	suppress	the	TME	via	production	of	IL-10	(154,	155).	
In	 contrast	 to	 TH1-like	NKT  cells,	 TH2-like	NKT  cells	 are	 not	
capable	of	inducing	DC	maturation	and	do	therefore	not	induce	




(243,	 244).	 TH2-	 and	 Treg-like	 NKT  cell	 subsets	 might	 still	 be	
able	 to	 kill	 tumor	 cells,	 either	 via	 CD1d-dependent	 or	 CD1d-
independent	 mechanisms.	 However,	 overstimulated	 NKT  cells	
produce	large	amounts	of	immunosuppressive	cytokines,	resulting	
in	a	net	effect	of	immunosuppression.	TH2-	and	Treg-like	NKT cell	
subsets,	 therefore,	 counteract	 the	 antitumor	 effects	 of	 TH1-like	
NKT cells	and,	in	addition,	actively	promote	tumor	progression.
In	 conclusion,	we	discussed	 evidence	 supporting	our	hypo-
thetical	model	(Figure 5)	that	TH1-like	NKT cells	are	responsible	
for	initiating	effective	antitumor	immune	responses	during	early	
tumor	 development.	When	 NKT  cells	 become	 overstimulated	
and	 anergic	 due	 to	 tumor	 progression,	 a	 part	 of	 the	NKT  cell	
population	is	deleted	in	cancer	patients.	In	addition,	the	remain-
ing	NKT cells	lose	their	antitumor	function	and	start	facilitating	
immune	 escape	 and	 tumor	progression.	 In	 summary,	we	 illus-
trated	 three	 problems	 regarding	NKT  cells	 in	 cancer	 patients.	
First,	the	numbers	are	lower	compared	with	healthy	individuals.	
Second,	NKT  cells	 are	 often	 anergic	 in	 cancer	 patients.	Third,	
NKT cells	are	often	skewed	toward	immunosuppressive	TH2-like	
subsets.
CURReNT NKT CeLL-BASeD 







For	 instance,	 a	 phase	 I	 clinical	 trial	was	 executed	 in	which	
intravenous	 (i.v.)	 injections	 of	 50–4,800  µg/m2	 α-GalCer	 were	




administration,	 NKT  cells	 disappeared	 from	 the	 circulation	
within	24 h.	Although	not	 investigated	 in	details	 in	 this	 study,	
recovery	of	NKT cell	numbers	was	not	observed	within	a	week.	
Furthermore,	 increased	 serum	 levels	 of	 TNF-α	 and	 GM-CSF	
were	detected	in	five	patients	and	increased	serum	IFN-γ	levels	






>100-fold	 expansion	 of	 type	 I	 NKT  cells	 in	 5  patients	 upon	
i.v.	 injections	with	5 × 106	α-GalCer-pulsed	DC	(247).	Besides	
NKT  cell	 expansion,	 treatment	with	α-GalCer-pulsed	DC	 also	
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for	TH1-like	 type	 I	NKT  cells	 in	 antitumor	 immune	 responses	
and	emphasize	the	essential	need	for	expansion	of	this	NKT cell	
population	 in	 cancer	 patients.	 Hence,	 immunotherapeutic	
approaches	focused	on	skewing	NKT cells	toward	a	TH1	profile	
should	be	developed.
In	 later	 clinical	 trials,	 ex vivo-activated	 type	 I	 NKT  cells	
were	adoptively	 transferred	to	patients	diagnosed	with	NSCL,	
advanced	melanoma,	 or	 head	 and	 neck	 squamous	 cell	 carci-
noma,	in	some	cases	in	combination	with	α-GalCer-pulsed	APC	
(253–256).	 In	 this	 therapy,	 PBMC	obtained	 from	 the	 patient,	
i.e.,	by	leukapheresis,	were	cultured	in	the	presence	of	IL-2	and	









clinical	 responses	did,	 however,	 not	 correlate	with	 the	 induc-
tion	of	immunological	responses	in	blood	(i.e.,	increase	in	type	
I	NKT cell	numbers	and/or	IFN-γ-producing	type	I	NKT cells	










comparison	 to	 the	 tumor	 load.	 Obtaining	 sufficient	 numbers	
of	 type	 I	 NKT  cells	might	 be	 a	major	 challenge	 since	 type	 I	
NKT cell	numbers	are	low	in	general,	and	especially	in	patients	
with	cancer.
Recently,	 studies	 focused	 on	 increasing	 the	 specificity	 of	
NKT cells	by	transducing	them	with	chimeric	antigen	receptors	
that	are	not	HLA	or	CD1d	restricted	(58,	70,	257).	In	addition,	
α-GalCer/CD1d-antitumor	 fusion	 proteins	 were	 suggested	 as	
a	 treatment	 for	 cancer	patients.	 For	 instance,	α-GalCer-loaded	
CD1d	 molecules	 fused	 with	 an	 antibody	 fragment	 specific	













but	 in	 their	 regulatory	 function.	When	 the	appropriate	 subsets	
are	 activated	 (i.e.,	 TH1-like	 NKT  cells),	 NKT  cells	 might	 shift	
the	tolerogenic	and	immunosuppressive	state	of	both	innate	and	








I	 NKT  cells	 with	 α-GalCer.	 As	 addressed	 in	 our	 hypothetical	
model	(Figure 5),	NKT cells	may	switch	to	immunosuppressive	
functional	subsets	or	become	anergic	due	to	chronic	stimulation	
during	 cancer	progression	which	might	 explain	 the	 absence	of	
beneficial	 clinical	 responses	 in	 patients	 upon	 treatment	 with	








ment	 due	 to	 their	 important	 regulatory	 function.	 To	 improve	
NKT  cell-based	 immunotherapies	 for	 the	 treatment	 of	 cancer	
patients,	several	aspects	of	the	current	treatment	strategies	need	
further	attention.
expansion of the NKT Cell Population
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induction	of	NKT cell	anergy	and	generation	of	immunosuppres-
sive	NKT cell	subsets.
Prevention and Breaking of  
NKT Cell Anergy
Until	 now,	 only	 a	 limited	 number	 of	 studies	 focused	 on	 pre-
vention	 or	 breaking	 of	NKT  cell	 anergy.	 Parekh	 et  al.	 showed	






































in	a	minority	of	patients	 so	 far.	 In	 this	 review,	we	 illustrated	a	
hypothetical	 model	 regarding	 the	 role	 of	 NKT  cells	 in	 solid	
tumors	 based	 on	 their	 function	 and	 phenotype.	 During	 early	
tumor	development,	TH1-like	NKT cell	subsets	have	the	potential	
to	initiate	effective	antitumor	immune	responses	against	tumors.	
However,	when	NKT cells	 become	overstimulated	 and	 anergic	
during	 tumor	 progression,	 they	 lose	 their	 antitumor	 function	
and	 start	 facilitating	 immune	 escape.	The	 role	 of	NKT cells	 in	
cancer	might	therefore	be	more	dynamic	than	initially	thought.	
So	 far,	 studies	 have	 primarily	 focused	 on	methods	 to	 activate	
and	expand	the	type	I	NKT cell	population	in	patients,	but	the	
contribution	of	 functionally	 altered	NKT cells	 to	 the	 failure	of	
NKT cell-based	 immunotherapies	has	 been	 largely	 ignored.	 In	
this	 review,	we	 conclude	 that	 there	 should	 be	 three	 important	
focuses	of	future	research	in	cancer	patients:	(1)	expansion	of	the	
NKT cell	population,	 (2)	prevention	and	breaking	of	NKT cell	
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